Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taxonid is a brand name for nitazoxanide, a synthetic nitrothiazolyl-salicylamide derivative with broad-spectrum antiprotozoal and antiviral activity. It functions as a prodrug that is rapidly hydrolyzed to its active metabolite, tizoxanide. The primary mechanism of action against anaerobic protozoa and bacteria involves the non-competitive inhibition of the pyruvate:ferredoxin oxidoreductase (PFO) enzyme, which is essential for electron transfer reactions in anaerobic energy metabolism. Beyond its antiparasitic effects, nitazoxanide has demonstrated antiviral properties by interfering with host-regulated pathways involved in viral protein biogenesis and inhibiting the maturation of viral glycoproteins. It is primarily indicated for the treatment of diarrhea caused by *Giardia lamblia* or *Cryptosporidium parvum* and has been investigated for its potential in treating viral respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taxonid.